Pfizer Pleads Guilty in Drug Marketing Case
- Share via
Pfizer Inc. formally pleaded guilty to charges that its Warner-Lambert subsidiary violated federal law by promoting non-approved uses for one of its drugs.
As part of a settlement with the government, Pfizer agreed last month to plead guilty to two counts of violating the Food, Drug and Cosmetic Act and to pay $430 million in fines -- the second-largest criminal fine ever imposed in a healthcare fraud prosecution, according to the Justice Department.
Pfizer acknowledged that Warner-Lambert, a company it bought in 2000, spent hundreds of thousands of dollars promoting off-label uses for the anti-seizure drug Neurontin.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
